IP Library Patent Application 12458164
Patent Application
App. No. 12/458,164

Combine radiation therapy and chemotherapy for treating cancer

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/458,164
Abstract

A method of treating a tumor of a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of alpha particles and a chemotherapeutic agent, wherein the alpha particles are administered by positioning a non-stable alpha-emitting radionuclide in proximity to and/or within the tumor, so as to administer a dose of alpha particles into the tumor, wherein the method does not comprise administration of an inhibitor of DNA repair, thereby treating the tumor of the subject.

Claims (23)

1 . A method of treating a tumor of a subject, the method comprising administering to the subject a therapeutically effective amount of alpha particles and a chemotherapeutic agent, wherein said alpha particles are administered by positioning a non-stable alpha-emitting radionuclide in proximity to and/or within the tumor, so as to administer a dose of alpha particles into the tumor, wherein the method does not comprise administration of an inhibitor of DNA repair, thereby treating the tumor of the subject.

2 . The method of claim 1 , wherein the tumor is a solid tumor.

3 . The method of claim 1 , wherein said non-stable alpha-emitting radionuclide is selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220.

4 . The method of claim 1 , wherein said positioning of said non-stable alpha-emitting radionuclide is effected by at least one radiotherapy device having a surface whereby said alpha-emitting radionuclide is on or beneath said surface.

5 . The method of claim 4 , wherein said at least one radiotherapy device comprises a wire.

6 . The method of claim 1 , wherein said non-stable alpha-emitting radionuclide is comprised in a solution.

7 . The method of claim 1 , wherein said positioning is effected at the base of the tumor.

8 . The method of claim 4 , wherein said at least one radiotherapy device comprises two radiotherapy devices.

9 . The method of claim 1 , wherein said tumor is selected from the group consisting of a squamous cell carcinoma tumor (SCC tumor), a pancreatic carcinoma tumor and a colon carcinoma tumor.

10 . The method of claim 1 , wherein said chemotherapeutic agent is selected from the group consisting of cisplatin, gemcitabine, is 5-fluorouracil (5FU), taxol and doxorubicin.

11 . The method of claim 1 , wherein when said tumor is a SCC tumor, said chemotherapeutic agent is cisplatin.

12 . The method of claim 1 , wherein when said tumor is a pancreatic carcinoma tumor, said chemotherapeutic agent is gemcitabine.

13 . The method of claim 1 , wherein when said tumor is a colon carcinoma tumor, said chemotherapeutic agent is 5-fluorouracil (5FU).

14 . A method of treating a tumor of a subject, the method comprising administering to the subject a therapeutically effective amount of alpha particles and a chemotherapeutic agent, wherein said chemotherapeutic agent is administered systemically, wherein said alpha particles are administered by positioning a non-stable alpha-emitting radionuclide in proximity to and/or within the tumor, so as to administer a dose of alpha particles into the tumor and wherein said chemotherapeutic agent is selected from the group consisting of cisplatin, gemcitabine, 5-fluorouracil (5FU), taxol and doxorubicin, thereby treating the tumor of the subject.

15 . The method of claim 14 , wherein the tumor is a solid tumor.

16 . The method of claim 1 , wherein said chemotherapeutic agent is a single chemotherapeutic agent.

17 . The method of claim 14 , wherein said non-stable alpha-emitting radionuclide is selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220.

18 . The method of claim 14 , wherein said positioning of said non-stable alpha-emitting radionuclide is effected by at least one radiotherapy device having a surface whereby said alpha-emitting radionuclide is on or beneath said surface.

19 . The method of claim 18 , wherein said at least one radiotherapy device comprises a wire.

20 . The method of claim 14 , wherein said non-stable alpha-emitting radionuclide is comprised in a solution.

21 . The method of claim 14 , wherein said positioning is effected at the base of the tumor.

22 . The method of claim 18 , wherein said at least one radiotherapy device comprises two radiotherapy devices.

23 . The method of claim 14 , wherein said tumor is selected from the group consisting of a squamous cell carcinoma tumor (SCC tumor), a pancreatic carcinoma tumor and a colon carcinoma tumor.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2016
From: ALTHERA MEDICAL LTD.
To: ALPHA TAU MEDICAL LTD.
Reel/Frame 038839/0876 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2014
From: RAMOT AT TEL-AVIV UNIVERSITY LTD.
To: ALTHERA MEDICAL LTD.
Reel/Frame 034103/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2009
From: KEISARI, YONA; KELSON, ITZHAK; COOKS, TOMER
To: RAMOT AT TEL AVIV UNIVERSITY LTD.
Reel/Frame 023082/0770 →